Novo Nordisk Q4: Slumping Due To Weak Guidance [Seeking Alpha]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Seeking Alpha
NVO's 2025 revenue rose 10% at constant currency rates, but margin compression and higher costs left net profit flat; the obesity franchise grew 31%. 2026 guidance forecasts ~9% constant currency revenue and profit decline, driven by U.S. drug pricing pressures and patent expirations. Oral Wegovy launch is outperforming peers; at 14x earnings, NVO stock offers long-term value for patient investors despite near-term headwinds. Looking for a helping hand in the market? Members of Cash Flow Club get exclusive ideas and guidance to navigate any climate. Learn More » Douglas Cliff/iStock Editorial via Getty Images Article Thesis Novo Nordisk A/S ( NVO ) reported its earnings results on Tuesday, with those results being more or less in line with expectations. Novo Nordisk's guidance for the current year, however, was weaker than what More on my IG service What Does Focusing On Cash Flow Get You? At Cash Flow Club , we focus on businesses with strong cash generation, ideal
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Patient preference is leaning towards Eli Lilly's weight loss drugs, says Guggenheim's Fernandez [CNBC]CNBC
- Eli Lilly Soars, Novo Nordisk Plummets On GLP/Obesity Updates - Here's What To Do [Seeking Alpha]Seeking Alpha
- Eli Lilly stock surges after company touts strong sales outlook as rival Novo Nordisk continues plunge [Yahoo! Finance]Yahoo! Finance
- Eli Lilly stock surges after company touts strong sales outlook as rival Novo Nordisk continues plunge [Yahoo! Finance Canada]Yahoo! Finance Canada
- Wegovy pill in high demand in weeks since launch, Novo Nordisk says [MSNBC.com]MSNBC.com
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 2/4/26 - Form IRANNOTICE
- 2/4/26 - Form 20-F
- 2/4/26 - Form 6-K
- NVO's page on the SEC website